Philip Seo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8825571/publications.pdf

Version: 2024-02-01

120 papers	9,428 citations	53660 45 h-index	39575 94 g-index
122 all docs	122 docs citations	122 times ranked	6099 citing authors

#	Article	IF	Citations
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	13.9	2,275
2	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	13.9	611
3	The antineutrophil cytoplasmic antibodyâ€“associated vasculitides. American Journal of Medicine, 2004, 117, 39-50.	0.6	459
4	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	2.9	271
5	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	2.9	249
6	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	2.9	231
7	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.5	218
8	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases, 2016, 75, 1166-1169.	0.5	196
9	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism, 2005, 52, 2168-2178.	6.7	171
10	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	1.5	147
11	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
12	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	2.6	143
13	Association of Granulomatosis With Polyangiitis (Wegener's) With HLAâ€“DPB1*04 and SEMA6A Gene Variants: Evidence From Genomeâ€Wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
14	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	3.0	137
15	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis and Rheumatology, 2016, 68, 1700-1710.	2.9	132
16	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	2.9	131
17	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. Journal of Rheumatology, 2015, 42, 1213-1217.	1.0	129
18	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the Rheumatic Diseases, 2014, 73, 1376-1379.	0.5	128

#	Article	IF	Citations
19	Neutrophilâ€Related Gene Expression and Lowâ€Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 1922-1932.	2.9	116
20	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. International Journal of Cardiology, 2016, 217, 135-148.	0.8	114
21	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.5	109
22	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-482.	1.6	109
23	Microscopic Polyangiitis. Rheumatic Disease Clinics of North America, 2010, 36, 545-558.	0.8	106
24	The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis. Journal of Rheumatology, 2011, 38, 1480-1486.	1.0	105
25	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	0.9	91
26	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	1.5	90
27	Alpha₁â€antitrypsin deficiencyâ€“related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and Rheumatism, 2010, 62, 3760-3767.	6.7	87
28	Cardiac Involvement in Granulomatosis with Polyangiitis. Journal of Rheumatology, 2015, 42, 1209-1212.	1.0	87
29	Patientâ€reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care and Research, 2010, 62, 1639-1645.	1.5	86
30	Large-vessel vasculitis. Arthritis and Rheumatism, 2004, 51, 128-139.	6.7	85
31	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. Journal of Rheumatology, 2011, 38, 1471-1479.	1.0	79
32	Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	2.9	79
33	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
34	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. Journal of Rheumatology, 2008, 35, 2017-23.	1.0	78
35	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	1.5	77
36	Myeloperoxidaseâ€“Antineutrophil Cytoplasmic Antibody (ANCA)â€“Positive and ANCAâ€Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis and Rheumatology, 2016, 68, 2945-2952.	2.9	75

#	Article	IF	Citations
37	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. Transplantation, 2011, 91, 1370-1375.	0.5	71
38	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	1.5	61
39	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2011, 63, 3988-3997.	6.7	59
40	Solid malignancies among etanerceptâ€treated patients with granulomatosis with polyangiitis (Wegener's): Longâ€term followup of a multicenter longitudinal cohort. Arthritis and Rheumatism, 2011, 63, 2495-2503.	6.7	58
41	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2015, 54, 1351-1359.	0.9	52
42	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	1.0	51
43	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 251-257.	2.2	50
44	Assessment of healthâ€related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2012, 64, 273-279.	1.5	49
45	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	2.9	49
46	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.5	47
47	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3â€"Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	2.9	45
48	Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2019, 48, 707-713.	1.6	43
49	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Kidney International Reports, 2018, 3, 1039-1049.	0.4	41
50	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	1.0	40
51	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.4	40
52	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	1.0	39
53	Pregnancy and Vasculitis. Rheumatic Disease Clinics of North America, 2007, 33, 299-317.	0.8	38
54	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. Journal of Rheumatology, 2016, 43, 1078-1084.	1.0	37

#	Article	IF	Citations
55	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2203-2211.	0.9	37
56	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	1.0	35
57	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). PLoS ONE, 2015, 10, e0121737.	1.1	35
58	Assessment of damage in vasculitis: expert ratings of damage. Rheumatology, 2009, 48, 823-827.	0.9	34
59	Metaâ€analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3463-3471.	6.7	33
60	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Journal of Nephrology, 2016, 29, 195-201.	0.9	33
61	Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: an observational study from India and North America. Rheumatology, 2020, 59, 1118-1127.	0.9	33
62	The future of damage assessment in vasculitis. Journal of Rheumatology, 2007, 34, 1357-71.	1.0	33
63	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	1.0	32
64	Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology, 2009, 21, 3-9.	2.0	31
65	Current Status of Outcome Measure Development in Vasculitis. Journal of Rheumatology, 2014, 41, 593-598.	1.0	31
66	Evaluation of damage in giant cell arteritis. Rheumatology, 2018, 57, 322-328.	0.9	28
67	Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy. Journal of Rheumatology, 2012, 39, 1413-1417.	1.0	27
68	Wegener's granulomatosis: managing more than inflammation. Current Opinion in Rheumatology, 2008, 20, 10-16.	2.0	26
69	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
70	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 535-544.	2.9	25
71	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	2.9	25
72	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	1.6	25

#	Article	IF	Citations
73	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	3.2	24
74	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Autoimmunity, 2019, 105, 102302.	3.0	24
75	Smallâ€vessel and mediumâ€vessel vasculitis. Arthritis and Rheumatism, 2007, 57, 1552-1559.	6.7	23
76	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1879-1887.	2.9	23
77	The Pharmacogenomic Association of FcÎ³ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	2.9	21
78	Clinical Manifestations and Longâ€Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	0.9	21
79	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	0.9	20
80	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	1.0	20
81	ANCA-Associated Vasculitis Pathogenesis: A Commentary. Current Rheumatology Reports, 2017, 19, 15.	2.1	19
82	Correspondence on â€œSARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune responseâ€•by Bonelli et al. Annals of the Rheumatic Diseases, 2021, 80, e164-e164.	0.5	17
83	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. PLoS ONE, 2012, 7, e30197.	1.1	16
84	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American Journal of Nephrology, 2017, 46, 231-238.	1.4	15
85	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 114-118.	0.4	14
86	Vasculitis in the intensive care unit. Best Practice and Research in Clinical Rheumatology, 2013, 27, 95-106.	1.4	13
87	Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. BMC Nephrology, 2015, 16, 88.	0.8	13
88	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Frontiers in Immunology, 2020, 11, 2053.	2.2	12
89	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Research and Therapy, 2022, 24, .	1.6	12
90	Otolaryngological Progression of Granulomatosis with Polyangiitis after Systemic Treatment with Rituximab. Otolaryngology - Head and Neck Surgery, 2014, 150, 68-72.	1.1	11

#	Article	IF	Citations
91	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	1.5	11
92	Expression of the sea urchin MyoD homologue, SUM1, is not restricted to the myogenic lineage during embryogenesis. Mechanisms of Development, 1999, 86, 209-212.	1.7	10
93	Renal Transplant in Wegenerâ€™s Granulomatosis Compared to Microscopic Polyangiitis. Journal of Rheumatology, 2010, 37, 1705-1708.	1.0	9
94	Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Seminars in Arthritis and Rheumatism, 2014, 43, 778-783.	1.6	9
95	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. Kidney International Reports, 2021, 6, 2903-2907.	0.4	8
96	Advances in Therapy for ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 509-515.	2.1	7
97	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	2.3	7
98	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	1.1	6
99	Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis. Otolaryngology - Head and Neck Surgery, 2021, 165, 019459982110042.	1.1	6
100	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 2020, 5, .	2.3	6
101	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCAâ€Associated</scp> Vasculitis. ACR Open Rheumatology, 2022, 4, 168-176.	0.9	6
102	Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy. Cureus, 2018, 10, e2372.	0.2	5
103	SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. Kidney International Reports, 2022, 7, 629-632.	0.4	5
104	Cases from the medical grand rounds of the osler medical service at Johns Hopkins University. American Journal of Medicine, 2002, 112, 730-732.	0.6	4
105	Vasculitis: lessons learned. Current Opinion in Rheumatology, 2009, 21, 1-2.	2.0	4
106	Macular lymphocytic arteritis: Clinical-pathologic correlation of a rare vasculitis. JAAD Case Reports, 2017, 3, 116-120.	0.4	4
107	Cases from the Osler Medical Service at Johns Hopkins University. American Journal of Medicine, 2002, 113, 522-524.	0.6	3
108	Biologic agents in systemic vasculitis. International Journal of Clinical Rheumatology, 2011, 6, 453-462.	0.3	3

#	Article	IF	Citations
109	Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE). Cureus, 2018, 10, e2949.	0.2	3
110	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 98-101.	0.4	3
111	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.4	3
112	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	0.9	2
113	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	0.6	2
114	Eosinophilic Granulomatosis with Polyangiitis: Challenges and Opportunities. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 520-521.	2.0	1
115	Vasculitides. , 2008, , 427-434.		1
116	Polyarteritis Nodosa: The Great Mimicker, Mimicked. Southern Medical Journal, 2008, 101, 351-352.	0.3	1
117	Cases from the Osler Medical Service at Johns Hopkins University. American Journal of Medicine, 2002, 112, 667-669.	0.6	0
118	Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis. Current Immunology Reviews, 2011, 7, 423-428.	1.2	0
119	053.â€ƒCLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
120	Life-Threatening Presentations of ANCA-Associated Vasculitis. , 2011, , 101-117.		0